Optimization of transfection methods for human lymphoblast TK6 cell line
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index; none of the 62 sources its claims cite is checked for support yet.
Abstract
Transfection has recently gained attention in the field of biomedical research due to its ability to manipulate gene expression. Every mammalian cell type has a characteristic set of requirements for optimal transfection. Some cells can be difficult to transfect and require optimization for successful transfection. Human lymphoblast TK6 cell line, an important cell line for genotoxic studies, is known to be extremely hard to transfect. Thus, optimizing transfection methods for human lymphoblast TK6 are increasingly important. To accomplish this, TK6 human lymphoblasts were transfected with plasmid constructs that expressed green fluorescent protein (GFP) and NanoLuc® activity. We compared the transfection efficiency of three commercially available transfection reagents, including Amaxa 96-well Nucleofection procedure using various solutions (SF, SE, and SG), Lipofectamine LTX, and Metafectene Pro®. The transfection efficiency and toxicity of various reagents were tested by fluorescence microscopy, luciferase activity, and cell viability assays. Amaxa 96-well Nucleofection Solution SF was identified as the best transfection reagent due to its relatively high luciferase activity, acceptable cell viability (80%), and GFP transfection efficiency (80%). Optimal conditions for transfection utilized with this reagent included 0.4 μg of plasmid DNA, 1.8 × 105 cells, and using the DS 137 Nucleofector program.
Overview
CoChat Summary
TL;DR
This study compared Metafectene Pro, Lipofectamine LTX, and Amaxa 96-well Nucleofection for transfecting hard-to-transfect human TK6 lymphoblasts. Amaxa Nucleofection with Solution SF and program DS 137 was identified as optimal, yielding high GFP transfection efficiency, acceptable viability, and the strongest luciferase signal among the tested reagents.
Key findings
- Amaxa 96-well Nucleofection Solution SF with program DS 137 was best: the abstract reports optimized conditions of 0.4 µg plasmid DNA, 1.8 × 10^5 cells, 80% viability, and 80% GFP transfection efficiency; results report ~80% GFP efficiency and ~85% viability for 0.4 µg, with luciferase RLU ~5.4 × 10^5 (discussion reports RLU = 5.1 × 10^5 and toxicity ~15%). Amaxa yielded the strongest luciferase signal of the three reagents after 24 and 36 h.
- Metafectene Pro gave ~96% cell viability regardless of ratio, with maximal transfection efficiency at reagent:DNA ratio 3 using 1.0 µg DNA at 24 and 36 h, but no nanoluciferase activity was detected under optimal conditions, so it could not be used in this system.
- Lipofectamine LTX achieved at least 80% transfection efficiency with no significant toxicity at 24 and 36 h; luciferase activity was significantly greater than control, with a 30% increase at 36 h versus 24 h, and nanoluciferase expression around 1.8 × 10^5 RLU.
- In secondary Amaxa optimization, 0.4 µg DNA gave significantly greater viability than 0.5 µg at 24 and 36 h, with no significant difference in GFP efficiency between 0.4 and 0.5 µg; 0.4 µg pNL1.1CMV produced significantly greater luciferase activity than 0.5 µg, with maximal expression at 36 h.
Methods
- TK6 human p53-proficient B-lymphoblastic cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine and 10% FBS at 37°C/5% CO2; cells were passaged at 2.0 × 10^5 cells/ml, media changed every 36 h, and passaged 12–14 h before experiments.
- Plasmids used were pGFPmax (GFP), pNL1.1.CMV (nanoluciferase), and pNL1.2[Nluc] promoter-less control. Transfections used Metafectene Pro (ratios 1:2–1:6; 0.5/1.0 µg DNA), Lipofectamine LTX (0.5–1.0 µg DNA; PLUS 1.5–2.5 µl; lipofectamine 3.75–10.0 µl), and Amaxa 96-well Nucleofection (initial SE/SF/SG with 0.4 µg pmaxGFP; secondary SF with DS 137 and 0.4/0.5 µg pGFPmax or pNL1.1CMV).
- Assays at 24 and 36 h included GFP fluorescence microscopy for transfection efficiency (GFP+ cells divided by total cells by brightfield), Nano-Glo luciferase assay, and Vi-cell viability. Transfection experiments were conducted in duplicates and repeated twice; luciferase assays are reported as triplicates/duplicates.
Limitations
- The paper has no dedicated limitations section. Stated caveats include: Amaxa nucleofection was more toxic than the other methods due to long-lasting pulses or polarization from the electric field and gave overall weak but acceptable viability; Metafectene Pro produced no detectable nanoluciferase activity, possibly due to inhibition/interference with NanoLuc; and no single delivery method or reagent works for all cells, with cytotoxicity and efficiency varying by reagent, protocol, and cell type.
- Evident from the text: only one cell line (TK6) was tested; experiments were in duplicates and repeated twice; statistical tests are not named; some optimization/viability data are “not shown”; and reported values vary between abstract, results, and discussion (e.g., viability 80% vs ~85%; RLU ~5.4 × 10^5 vs 5.1 × 10^5).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
0 Valid · 0 Not valid · 19 Not checked · 52 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No signi cant (p>0.05)differences in cell viability between control cells that received no DNA and cells that were transfected with various reagent/DNA ratios for both 24 and 36h post transfection (Fig 1A).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Transfection e ciency of cells that received pGFPmax was signi cantly (p<0.05)greater than the control cells that received no DNA (Fig. 1B).”
- Also stated in: § Optimizing transfection conditions for Metafectene Pro transfection reagent · plain
“Transfection e ciency of cells that received the pGFPmax plasmid was signi cantly (p<0.05)greater than control cells that received no DNA (Fig. 2B).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Optimizing transfection conditions for Metafectene Pro transfection reagent · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximal transfection e ciency was achieved at reagent to DNA ratios of 3 for both 24 and 36h post transfection (Fig. 1B).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Figure 1A cell viability (~96%) in this cell line using Metafectene® Pro was comparable regardless of the ratio (Fig 1A).”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, the results of Fig. 1 demonstrate that optimal transfection conditions for the Metafectene Pro transfection reagent occur at reagent/DNA ratio of 3 when 1.0ug of DNA is utilized for transfection.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Metafectene Pro transfection reagent
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 71 claims and every source verdict.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Abstract
“E cient conditions for transfection utilized with this reagent included 0.4µg of plasmid DNA, 1.8 x 10 5 cells, and the DS 137 nucleofector program.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Secondary nucleofection optimization
“The cells were re-suspended to a density of 1.0 x 10 6 cells/20ul in the supplemented nucleofection solution SF (Lonza).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Lipofectamine transfection
“TK6 cells were seeded in 6-well plates at a density of 1.0 x 10 5 and 1.0 x 10 6 cells/well.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Optimizing transfection conditions for Lipofectamine LTX
“cells were seeded in 6-well plates at 0.5 x 10 5 and 1.0 x 10 6 cells/well”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Secondary optimization of nucleofection conditions by using the Amaxa nucleofector
“Luciferase activity was RLU ~5.4 X10 5 , as opposed to 1.8X10 5 RLU obtained for lipofectamine LTX.”
§ Comparison and optimization of transfection methods for human lymphoblast TK6 cell line > Discussion
“In this study transfecting TK6 with 0.4µg of plasmid DNA using reagent SF, program DS 137 as was associated with high transfection e ciency (~ 80%) and luciferase activity (RLU = 5.1 X 10 5 ) with acceptable cell toxicity (~ 15%).”
Citations
Cites
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Dalby, B. (2004) · Methods · doi:10.1016/j.ymeth.2003.11.023 · Cited by 619
Nanomedicine : nanotechnology, biology and medicine.
ScienceDirect (2005) · Cited by 586
Physical methods for gene transfer: Improving the kinetics of gene delivery into cells
MEHIERHUMBERT, S., & GUY, R. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.007 · Cited by 395
DNA Nanoparticles and Development of DNA Delivery Vehicles for Gene Therapy
Vijayanathan, V., Thomas, T., & Thomas, T. J. (2002) · Biochemistry · doi:10.1021/bi0203987 · Cited by 360
Satkauskas, S., Bureau, M. F., Puc, M., Mahfoudi, A., Scherman, D., Miklavcic, D., & Mir, L. M. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0526 · Cited by 306
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes
Ganesh, L., Burstein, E., Guha-Niyogi, A., Louder, M. K., Mascola, J. R., Klomp, L. W. J., Wijmenga, C., Duckett, C. S., & Nabel, G. J. (2003) · Nature · doi:10.1038/nature02171 · Cited by 226
Transfection Techniques for Neuronal Cells: Table 1.
Karra, D., & Dahm, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0183-10.2010 · Cited by 209
An Efficient Low Cost Method for Gene Transfer to T Lymphocytes
Chicaybam, L., Sodre, A. L., Curzio, B. A., & Bonamino, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060298 · Cited by 129
Hu, B., Zou, Y., Zhang, L., Tang, J., Niedermann, G., Firat, E., Huang, X., & Zhu, X. (2019) · Human Gene Therapy · doi:10.1089/hum.2017.234 · Cited by 124
Research works printed but not linked: 4
- Karra D, Dahm R. Transfection techniques for neuronal cells. Journal of Neuroscience. 2010 May 5;30(18):6171-7.
- Park JS, Surendran S, Kamendulis LM, Morral N. Comparative nucleic acid transfection e cacy in primary hepatocytes for gene silencing and functional studies. BMC research notes. 2011 Dec;4(1):1- 8.
- Parson II CD. A Generalizable Method to Normalize Luciferase Activity in Transiently Transfected B cells (Doctoral dissertation, North Carolina Agricultural and Technical State University).
- Badakov R, Jaźwińska A. E cient transfection of primary zebra sh broblasts by nucleofection. Cytotechnology. 2006 Jun 1;51(2):105-10.
Cited by
Hosseini-Kharat, M., Bremmell, K. E., Grubor‐Bauk, B., & Prestidge, C. A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.002 · Cited by 39
Jamour, P., Jamali, A., Langeroudi, A. G., Sharafabad, B. E., & Abdoli, A. (2024) · BMC Molecular and Cell Biology · doi:10.1186/s12860-024-00511-x · Cited by 13
Pelle, G. D., Markelc, B., Čerček, U., Živič, U., Coupard, M., Šribar, J., Križaj, I., Arshad, M. S., Božič, T., Gazvoda, L., et al. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214537 · Cited by 4
Metadata
- Authors
- Ewunkem, A. J., & Agee, K.
- Affiliations
- Winston-Salem State University (US)
- ORCID
- Ewunkem, Akamu Jude
- Venue
- Gene & Protein in Disease
- Publisher
- AccScience Publishing
- Published
- 2023-05-29
- Volume
- 2
- Issue
- 2
- Pages
- 0353
- ISSN
- 2811-003X (ISSN-L)
- OpenAlex
- W4382073817
- Semantic Scholar
- b46f2c6154d46cc7d57ec8b759edf74e0ccfcbb0
- Cited by
- 3
- References
- 73
- Citations by year
- 2025: 1 · 2024: 2
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Gene & Protein in Disease (publishedVersion, cc-by)
- Research Square (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (S06GM076530)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- transfection optimization, transfection reagents, nucleofection, transfection efficiency, cell viability, genotoxicity testing, plasmid DNA delivery, GFP expression, NanoLuc luciferase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimization of transfection methods for human lymphoblast TK6 cell line. https://app.cochat.ai/papers/10.36922/gpd.0353
- The paper
- Ewunkem, A. J., & Agee, K. (2023). Optimization of transfection methods for human lymphoblast TK6 cell line. Gene & Protein in Disease. https://doi.org/10.36922/gpd.0353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.




